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The Accelerating Medicines Partnership (AMP) Lupus 
Network was established as a partnership between the 
National Institutes of Health, pharmaceutical companies, 
nonprofit stakeholders, and lupus investigators across 
multiple academic centers to apply high- throughput tech-
nologies to the analysis of renal tissue, urine, and blood 
from patients with lupus nephritis (LN). The AMP network 
provides publicly accessible data to the community with 
the goal of generating new scientific hypotheses and im-
proving diagnostic and therapeutic tools so as to improve 
disease outcomes. We present here a description of the 
structure of the AMP Lupus Network and a summary of 
the preliminary results from the phase 1 studies. The suc-
cessful completion of phase 1 sets the stage for analysis 
of a large cohort of LN samples in phase 2 and provides 
a model for establishing similar discovery cohorts.
Introduction
LN is a serious complication of systemic lupus erythe-
matosus (SLE) that affects nearly 40% of patients, with even 
higher rates in minority populations. Despite intense research 
efforts, treatment options remain inadequate, and the develop-
ment of novel therapies has been slow. End- stage renal dis-
ease and death are common complications in patients with LN 
(1,2). While histologic classification drives the choice of treat-
ment for LN, this classification is only loosely correlated with 
patient outcome (3–5). The presence of tubular injury, tubuloin-
terstitial inflammation, and/or interstitial fibrosis is associated 
with a poorer prognosis of LN (6–8); however, these are late 
manifestations of LN that reflect the inability to detect early 
disease and to treat effectively. This failure likely reflects our 
limited knowledge of the molecular mechanisms driving kidney 
damage. Thus, there is a critical need for a comprehensive and 
high- resolution analysis of tissue and immune cells in LN to 
identify new drug targets and disease biomarkers.
A central challenge of LN has been identifying disease sub-
sets among patients that can be therapeutically targeted. Path-
ogenic mechanisms inferred from genetic studies have not yet 
led to effective therapeutic interventions. Animal models are also 
imperfect because their relationship to human disease is not well 
defined, and successful interventions have not yet translated to 
improved patient outcomes. Some progress has been made in 
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stratifying patients with lupus based on molecular analyses of 
whole blood and lymphocyte subsets. Longitudinal monitoring of 
whole- blood gene expression in 158 pediatric patients identified 
7 lupus subgroups as well as a distinct neutrophil signature that is 
enriched in patients with LN and decreases after treatment. Abnor-
malities in cell activation remain even after treatment, with differ-
ences among nephritis subclasses that suggest differences in the 
underlying pathogenic mechanisms (9). A CD8 T cell exhaustion 
signature in the peripheral blood is associated with a better overall 
prognosis of patients with lupus but not with disease activity per 
se (10). Nevertheless, how pathogenic mechanisms drive molec-
ular stratification of LN remains poorly understood both because 
whole blood profiling yields insufficient molecular resolution for 
mechanistic inferences and because changes in the peripheral 
blood may not reflect the disease processes in the tissue.
The primary goal of the AMP Lupus Network is to improve 
our understanding of LN pathogenesis by applying new technol-
ogies to the analysis of renal tissue, urine, and blood in order to 
identify novel targets for drug development and improve diagnos-
tic classification. Supported by the National Institutes of Allergy 
and Infectious Diseases, the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases, pharmaceutical companies, 
and nonprofit organizations across the US, the AMP Lupus Net-
work is comprised of academic centers and investigators focused 
on directly studying patient samples. The Network applies single- 
cell molecular profiling and other high- throughput approaches to 
generate disease- specific, publicly accessible data to the greater 
biomedical community for further investigations. The driving ques-
tions include: Which cell types, cell states, and molecular pro-
grams are associated with LN disease activity and responsiveness 
to therapy? Can surrogate molecular markers (e.g., from urine, 
blood leukocytes, and/or skin biopsy samples) be leveraged for 
diagnostic or prognostic purposes?
Structure of the AMP
The AMP Lupus Network consists of 5 technology and clinical 
centers and a network of clinicians who collect patient data and 
tissue samples. These centers are supported by an  administrative 
arm, shared with the AMP Rheumatoid Arthritis Network, that 
oversees data collection, tissue storage, and other logistics and 
by a network of scientific subcommittees each focused on a par-
ticular cell subtype or analytic approach (Figure 1 and Table 1). 
Regularly scheduled conference calls ensure the cohesiveness 
of the geographically diverse groups, and face- to- face meetings 
occur as needed. Shared data has been loaded into ImmPort 
(www.immpo rt.org; study SDY997).
Clinical design of the AMP and specimen 
 collection
The goals and clinical design of each phase of the AMP Lupus 
Network are shown in Figure 2. Patients recruited into phase 1 of 
AMP for the SLE component met the following criteria: American 
College of Rheumatology (ACR) (11) or the Systemic Lupus Inter-
national Collaborating Clinics (SLICC) classification criteria for SLE 
(12), clinical and laboratory data consistent with LN, and the need 
for a kidney biopsy to guide clinical care regardless of whether this 
was a first or repeat biopsy. For phase 1, only patients with urine 
protein- to- creatinine ratios (UPCRs) >1.0 gm/dl were included; 
however, for phase 2, patients with UPCRs >0.5 gm/dl are being 
included. Adult patients of any race/ethnicity or sex were enrolled. 
Only individuals with International Society of Nephrology/Renal 
Pathology Society histologic class III, IV, or V (or a mixed class 
that included 1 of these) were included in the pipeline analyses 
for phase 1 (Figure 3). Patients received standard- of- care therapy 
at the discretion of the treating physician. Clinical correlations will 
be performed in phase 2. Clinical follow- up was performed, and 
blood and urine samples were obtained according to protocol at 
3, 6, and 12 months. If patients underwent a second biopsy, this 
sample was also collected. As expected, some technical varia-
tion was present across the various sites, including the size of the 
biopsy needle and length of the biopsy.
For the phase 1 program, 57 LN and 15 living trans-
plant donor (LD) renal biopsy samples from unperfused freshly 
removed organs were collected from 10 sites over 15 months. 
A total of 45 individuals with class III, IV, or V pathology and 12 
LD controls were included in the phase 1 analytic pipeline. Data 
collected for each enrolled participant included demographic 
information (Table 2), age at SLE diagnosis, ACR classification 
criteria, SLICC classification criteria, autoantibody titers, clinical 
laboratory values (such as C3, C4, creatinine, albumin), urinary 
parameters (urinalysis, UPCR), Safety of Estrogens in Lupus 
Erythematosus National Assessment version of the Systemic 
Lupus Erythematosus Disease Activity Index scores, physician 
global assessment, Patient- Reported Outcomes Measurement 
Information System–29 profile, medications, and adverse events. 
Research electronic data capture forms were used for data entry; 
a study- specific database was created and maintained by the 
AMP Leadership Center.
SIGNIFICANCE & INNOVATIONS
• Successful completion of phase 1 of the Acceler-
ating Medicines Partnership Lupus Network has 
yielded an optimized set of protocols for state-of-
the-art, high-throughput analysis of renal tissue, 
urine, and blood.
• The phase 1 studies have identified novel inflam-
matory renal cell populations and their origins and 
have begun to identify possible molecular biomark-
ers for disease response.
• Exploratory studies have revealed the potential of 
using noninvasive cell collections (urine and skin) to 
longitudinally study the renal landscape.
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Renal biopsies were collected and stored as described 
(13,14). Although some fresh samples were individually processed 
in the early phases of the study, protocol optimization performed 
in phase 0 and phase 1 showed that immediate freezing of tis-
sue samples followed by later thawing and dissociation at a single 
technology site yielded high-quality RNA, ample for downstream 
applications without a freezing- associated molecular signature 
(13). This protocol was therefore adopted for all AMP tissue sam-
ples. Blood was processed for serum, plasma, peripheral blood 
mononuclear cells (PBMCs), and total blood leukocytes, and urine 
was collected and processed using optimized protocols (13,14). 
For phase 2, all samples will be shipped to a single site for storage 
and subsequent redistribution to the technology sites.
Single- cell RNA sequencing methods and  
reproducibility
Single- cell RNA sequencing (scRNAseq) is transforming 
biomedicine by uncovering new cell types and cellular functions 
in complex biologic tissues (15). Thousands of single cells from 
Figure 1. The structure and goals of the Accelerating Medicines Partnership (AMP): overall structure and integration of the AMP Lupus 
Network (footnotes shown in Table 1). NIH = National Institutes of Health; NIAMS = National Institute of Arthritis and Musculoskeletal and Skin 
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individual tissue samples can now be processed in parallel for 
deep molecular profiling by next- generation sequencing (NGS). 
Unbiased bioinformatic analysis enables the identification, char-
acterization, and molecular relationships among individual cells. 
Because scRNAseq is rapidly evolving, the AMP Lupus Network 
has adopted contemporary scRNAseq approaches to enable 
state- of- the- art cellular profiling.
The phase 1 studies used both plate- based (Cel- Seq2) (13) 
and Fluidigm platforms (C1 chip) (14) to profile transcriptomes of 
single cells. Plate- based technology enabled deep gene profiling 
of sorted CD45+ cells for improved cellular characterization but 
was labor intensive and low throughput; the Fluidigm platform 
was agnostic, easy to use, and improved throughput but cap-
tured fewer genes. These methods were applied to 45 patient 
samples (21 by Fluidigm and 24 by Cel- Seq2) to reveal for the 
first time the molecular details of diseased renal parenchymal 
cells and activated immune cells from tissue at unprecedented 
resolution (13,14).
Recently, droplet- based approaches have dramatically 
increased the number of cells that can be profiled in parallel as 
well as the number of genes detected (16). Single cells are par-
titioned into nanoliter- scale droplets containing barcoded beads 
that capture gene transcripts for NGS. Droplet- based scRNAseq 
(10x Genomics) will be applied to patient samples in phase 2. 
Thousands of renal cells will be analyzed per sample, thus allow-
ing discovery of rare cell populations and enabling new molecular 
insights while presenting new challenges in data analysis. Sev-
eral bioinformatic tools have recently been developed that enable 
analysis of multiple data sets by minimizing the effects of com-
bined analysis of different scRNAseq technologies (17,18).
The general data analysis pipeline for the phase 1  studies 
is shown in Figure 3. First, major cell types were identified by 
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Table 1.  (Cont’d)
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 grouping the profiled cells into clusters sharing similar gene 
expression patterns, and then further subclustering was per-
formed to reveal cell subtypes. Cluster labeling was done 
using a combined approach, taking into account the distribu-
tion of known lineage markers across clusters, the identity of 
genes specifically upregulated in each cluster, and by com-
paring the gene expression data of each cluster to those of 
published reference data sets (19–21). Understanding which 
pathways are active in each cell type was elucidated through 
pathway enrichment and gene ontology analyses (22,23) and 
enrichment programs such as DAVID (24) or Enrichr (25). 
Developmental trajectories were revealed by linking cell types 
to progenitor populations (26). Importantly, phase 1 estab-
lished the feasibility for a much larger phase 2 study of 160 
LN patients that is currently underway, with initial sample col-
lection almost complete (Figure 2).
Single- cell RNAseq analysis of dissociated tissue raises 
powerful new hypotheses but has several important technical 
limitations (15). First, tissue disaggregation destroys spatial con-
text among cell types and may deplete some cell populations for 
downstream analyses or introduce stress signatures. We have 
found, for example, that kidney epithelial cells are particularly sen-
sitive to cell death and/or cell stress upon disaggregation. Sec-
ond, low abundance RNAs may not be detected so that important 
information about cell function may be missed. Third, scRNAseq 
profiles RNA transcriptomes, which are only an indirect readout of 
protein expression and cellular function. Recent advances include 
multiplexed fluorescent in situ hybridization of tissue sections that 
gives critical information about the spatial context of multiple cell 
types, as well as multimodal analysis of single cells to add infor-
mation about cell surface markers, protein abundance, and epi-
genomic state (15). These advances are occurring in parallel with 
the development of new methods to integrate multimodal data 
and compare data sets from different experiments. While these 
technologies are too new to be applied in the AMP studies, it is 
expected that they will soon become possible in the setting of 
cohort studies of disease such as those described here. Finally, 
construction of a Human Cell Atlas (https ://www.human cella tlas.
org) will allow easier comparisons of disease states with normal 
tissue.
Summary of scRNAseq data from the phase 1 
studies
Studies of whole kidney and skin. Both kidney and skin 
were analyzed by the METRO group (Table 1). Biomarkers availa-
ble from skin biopsies would be a desirable option, given the eas-
ier accessibility of skin as compared to kidney tissue. The concept 
that skin can reflect the immunologic milieu of SLE dates back to 
the original demonstration of immunoglobulin and complement 
deposition at the dermal–epidermal junction in both lesional and 
nonlesional skin (25). Activation of the microvasculature is found 
even in non–sun- exposed, nonlesional skin of patients with active 
lupus (26–28), and endothelial changes in the kidneys of patients 
with LN predict poor responses to therapy (29). Thus, serial 
analysis of noninvolved skin, although distant from the primary 
affected organ, may provide an opportunity to explore surrogates 
for renal tissue analyses so as to facilitate early identification criti-
cal to renal survival and follow treatment responses. Accordingly, 
2- mm biopsy samples from nonlesional, non–sun- exposed skin 
(buttocks) were collected from patients donating renal tissue as 
part of AMP.
Using a C1 Autoprep system (Fluidigm), skin samples from 
subjects with LN, healthy skin samples from control subjects, 
and renal biopsy samples were examined by scRNAseq without 
presorting or cell- type selection. A total of 21 LN kidney biopsy 
samples and 17 skin biopsy samples were analyzed in phase 1 
(14). Graph- based clustering and t- distributed Stochastic Neigh-
bor Embedding visualization (30) resolved major skin and kidney 
cell populations, including tubular cells, keratinocytes, endothelial 
Figure 2. The structure and goals of the Accelerating Medicines Partnership (AMP): goals and enrollment criteria for each phase of the lupus 
nephritis studies. CytoF = cytometry by time- of- flight mass spectrometry; LN = lupus nephritis; PBMCs = peripheral blood mononuclear cells; 
SLE = systemic lupus erythematosus; ACR = American College of Rheumatology; SLICC = Systemic Lupus International Collaborating Clinics; 
UPCR = urine protein- to- creatinine ratio.
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Development & validation of 
standardized protocols for 
single-cell isolation
Optimization of RNAseq & CytoF 
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Adult patients of any race/ethnicity or gender
Diagnosis of SLE by ACR or SLICC criteria
Age 16–60 years

















Novel therapeutic target identification
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Evaluation of cellular gene expression profiles in LN
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HOOVER ET AL 238       |
Figure 3. The Accelerating Medicines Partnership (AMP) Lupus Network Pipeline. Samples and clinical data are collected at point of care 
(red box). Patient data is loaded into research electronic data capture (REDCap) and samples are processed according to optimized protocols 
and shipped to the sample and tissue repository for distribution to the technical sites. Proteomic analyses, cytometry by time- of- flight mass 
spectrometry (CytoF), and single- cell RNA sequencing are each performed at different technical sites (blue box), and data analyses and 
integration (green box) are performed by the scientific groups. Examples of analyses and integration methods are shown in the bottom panel. 
Profiled cells are grouped into clusters sharing similar gene expression patterns (step 1). The dimensionality of the expression data of these 
genes is reduced using principal components analysis, and the resulting low- dimensional data is analyzed using graph- based clustering 
(step 2a). Further subclustering reveals cell subtypes (step 2b). Cluster labeling is performed by taking into account the distribution of known 
lineage markers across clusters and the identity of genes specifically upregulated in each cluster, and by comparing the gene expression data 
of each cluster to those of published data sets of reference samples (step 2c). Individual gene expression (violin plot) in each cell subtype can 
be generated (step 3). Pathway enrichment analysis using curated databases and gene ontology analysis provides information about which 
genes are active in each pathway (step 4). Developmental trajectories are constructed by linking cell types to progenitor populations (step 5), 
and regulatory relationships can be inferred between genes using cellular interdependency networks (step 6). Cluster analysis of CytoF data 
is displayed as a t- distributed Stochastic Neighbor Embedding (tSNE) plot (box). Phase 2 will integrate multimodal data to address the goals 
shown in Figure 2 and to generate hypotheses.
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cells, fibroblasts, and leukocytes. Subtypes of skin and kidney 
epithelial cells were further resolved, including melanocytes, sweat 
gland cells, proximal and distal tubular cells, and collecting duct 
cells. This agnostic approach allowed us to focus on the epithe-
lial cells of both tissues, which were analyzed for prognostic and 
diagnostic markers.
Previously published phase 0 studies of LN keratinocytes 
(31) demonstrated an upregulated interferon (IFN) response sig-
nature compared to healthy keratinocytes from control subjects. 
This finding was replicated in phase 1 and further extended to 
tubular cells. Preliminary analysis of small numbers of LN patients 
with available follow- up data found that tubular cells from patients 
who did not respond to conventional therapy at 6 months 
post biopsy showed a higher IFN score and increased expres-
sion of genes encoding extracellular matrix (ECM) proteins and 
ECM interaction proteins, suggesting a fibrotic process. A trend 
toward up- regulation of both ECM pathways was also observed 
in keratinocytes of nonresponders (32). Exploration of the cellu-
lar interactions between various cell types in the kidney and skin 
suggest that the fibrotic process may be mediated through fibro-
blast growth factor receptors on the tubular cells whose ligand is 
expressed in leukocytes. Further preliminary analyses suggested 
that there might be gene signatures that distinguish histologic 
subclasses of disease. These findings need to be confirmed in the 
phase 2 studies. Resident renal cells also expressed high levels of 
chemokines with receptors expressed by leukocytes, indicating a 
potential mechanism for immune cell infiltration into the glomeruli 
and tubulointerstitium (14).
Studies of infiltrating immune cells. Viable CD45+ 
immune cells were sorted from renal biopsies from 24 LN and 
12 unperfused renal LDs, and scRNAseq was performed using 
Cel- Seq2 (13). Batch effects were minimal, allowing comparison 
of data from all the samples in a single analysis. We identified 21 
immune cell clusters in the patients with LN, including 10 subsets 
of natural killer (NK) and T cells, 4 clusters of B cells, 6 clusters of 
macrophages and dendritic cells, and 1 mixed cluster of dividing 
cells. Memory CD4 T cells and resident macrophages were the 
most frequently identified subsets in LDs. Saturation analysis indi-
cated that this initial cohort size was sufficient to identify most cell 
clusters. Comparisons between LN and LD cells indicated that 
an IFN signature is present in most cell types from the patients 
with LN.
Analysis of the transcriptome of each subset yielded several 
novel findings (13). Most of the dividing cells were CD8+ T cells 
and NK cells; these cells also expressed the most IFNγ. By con-
trast, Th1 and Th17 cytokine- expressing CD4 T cells were present 
in lower abundance without skewing to either subset. Novel CD8 
T cell subsets were identified in the tissue, but exhausted CD8 T 
cells were not detected, although these were readily identified in 
the peripheral blood. B cells of naive and activated phenotypes 
were detected, including B cells with an age- associated pheno-
type and plasma cells. Follicular helper T cell–like CD4 T cells were 
also found, confirming previous data showing that T cell and B 
cell activation occur in situ (33). Macrophages, myeloid dendritic 
cells, and plasmacytoid dendritic cells were all found. Analysis of 
the macrophage subsets showed 3 subpopulations (CM0, CM1, 
and CM4) that appeared related by trajectory analysis. These cells 






Female 52 (92) 11 (73)
Male 5 (9) 4 (27)
Race
Asian 7 (12) 0
African American 23 (40) 3 (20)
Unknown or not reported 3 (5) 1 (7)
White 25 (43) 11 (73)
Ethnicity
Hispanic or Latino 17 (30) 2 (13)
Not Hispanic 40 (70) 13 (87)
Age at biopsy, mean ± SD 
years






Mycophenolic acid 1 (2)
Mycophenolate mofetil 14 (25)
dsDNA+ (n = 48) 40 (83)
Low C3 (n = 56) 42 (75)










Activity, mean ± SEM (range) 
(n = 37)
4.69 ± 0.78 
(0–16)§
Chronicity, mean ± SEM 
(range) (n = 37)
1.95 ± 0.29 
(0–7)¶
ACR 1997 score (n = 57) 5.84
SLICC score (n = 51) 7.80
SELENA–SLEDAI score  
(n = 57)
12.93
ACR/SLICC Damage Index  
(n = 51)
3.99
* Values are number (%) unless indicated otherwise. AMP = Accel-
erating Medicines Partnership; SLE = systemic lupus erythematosus; 
ISN/RPS = International Society of Nephrology/Renal Pathology So-
ciety; ACR 1997 = American College of Rheumatology 1997 update 
of the SLE revised criteria; SLICC = Systemic Lupus International 
Collaborating Clinics; SELENA–SLEDAI = Safety of Estrogens in Lupus 
Erythematosus National Assessment version of the Systemic Lupus 
Erythematosus Disease Activity Index. 
† A total of 45 lupus nephritis and 12 living transplant donor controls 
were analyzed in phase 1, and the others were rolled over to phase 2. 
‡ Class VI biopsies were excluded. 
§ Maximum 24. 
¶ Maximum 12. 
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most resembled CD16+ peripheral monocytes (34). Of these, the 
subset most similar to peripheral blood monocytes (CM0) had an 
inflammatory phenotype, which was lost as the cells progressed 
along the trajectory; instead, these cells first acquired a phago-
cytic (CM1) and then an alternatively activated (CM4) phenotype. 
These alternatively activated cells were also a major immune cell 
source of chemokines, suggesting that they may help orchestrate 
immune cell infiltration and/or organization. CXCR4 and CX3CR1 
were the most commonly expressed chemokine receptors among 
the immune cells (13).
The question of noninvasive methods for evaluation of renal 
status was addressed by analyzing urine samples from 8 patients 
with LN. Of note, not all of the renal immune cells have access to the 
urinary space or survive in the urine; compared to kidney cells, urine 
cells had a lower frequency of T cells and instead were dominated 
by a single cluster of CD16+ macrophages (cluster CM1). Despite 
the limited diversity of urine immune cells, their transcriptome faith-
fully reflected that of the kidneys, indicating that the urine can be 
used to estimate gene expression of the related kidney cells (13).
Analysis of urine using proteomics
Numerous proteins that participate in the pathophysiology 
of LN can be measured in the urine, and several distinguish the 
urine of patients with active LN from that of patients with inactive 
disease. Nevertheless, longitudinal studies have been few, and 
there is as yet no biomarker panel that is superior to standard 
clinical parameters for predicting LN outcomes (35,36). High- 
throughput proteomic analysis of urine from patients enrolled in 
the AMP and followed longitudinally for a year will accelerate the 
pace of discovery of useful LN biomarkers, identify proteomic 
signatures with greater specificity and sensitivity than a single 
protein, and help provide additional insights into the underlying 
biology of the disease process. Furthermore, the ability to cor-
relate proteomic signatures with molecular signatures will greatly 
enhance the power of this approach.
Two urine proteomics platforms were tested in phase 1 to 
demonstrate feasibility and identify potential biomarker targets. 
The first was Quantibody, an array- based, multiplex, enzyme- 
linked immunosorbent assay (ELISA) system (Raybiotech) for 
simultaneous quantitative measurement of 1,000 proteins from 
small urine volumes, including multiple cytokines, growth  factors, 
proteases, and soluble receptors. This assay is highly repro-
ducible and combines the high specificity and sensitivity of ELISA 
with the high throughput of the glass chip- based array. For some 
molecules, the sensitivity of the arrays far exceeds that of ELISA 
assays (37,38). The second approach was a capillary electropho-
resis/mass spectroscopy platform that separates and identifies 
up to 5,000 peptides in the urine with high resolution, sensitivity, 
and reproducibility. This technology can differentiate chronic kid-
ney disease from LN using a classification panel of peptides (39). 
Preliminary screens of phase- 1 urine samples have shown a large 
number of elevated proteins and peptides in the urine of patients 
with LN compared to urine from healthy controls, demonstrating 
the feasibility of using these 2 proteomic methods in AMP (Petri M: 
personal communication).
Questions that can now be addressed in phase 2 are whether 
it is possible to differentiate histologic classes or to identify treat-
ment responders. In addition, with the large number of proteins 
identified in the urine, it may be possible to perform pathway 
analyses similar to those performed using transcriptomic data. 
Integration of the 2 data sets would likely expand our understand-
ing of the pathophysiology of LN.
Analysis of peripheral blood subsets using 
cytometry by time- of- flight mass spectrometry 
(CytoF)
CytoF is a method for comprehensive and accurate, multidi-
mensional single- cell phenotyping that employs antibodies tagged 
with rare- earth metal isotopes rather than fluorescent- tagged anti-
bodies (38). This technology provides the opportunity to simulta-
neously stain cells with up to 45 different metal- tagged antibodies 
without major concern for signal spillover or background.
In phase 1 studies, optimization of cell processing and cryo-
preservation of both total leukocytes (TL) and PBMCs was fol-
lowed by building of CytoF antibody panels designed to detect 
major immune cell subset markers. Three PBMC and 2 TL panels 
were developed for phase 1 to inform the development of phase 
2 AMP CytoF panels. During the development period, pilot CytoF 
antibody panel stains were performed to assure proper staining 
antibody concentrations and to validate staining accuracy. Other 
approaches to improve data quality included flow cytometry con-
firmation of cell counts, an assessment of cell viability, use of plat-
inum isotope barcoding reagents for batched sample acquisition, 
and normalization of signal intensity during data acquisition. To 
reduce batch effects, the same Helios instrument was used for the 
entire phase 1 project, and samples were randomized into groups 
to include mixtures of controls and patient samples.
The entire AMP phase 1 blood phenotyping project analyzed 
34 control, 44 SLE, and 33 rheumatoid arthritis (RA) PBMC sam-
ples and 17 control, 36 SLE, and 21 RA TL samples (uploaded as 
a shared data set to ImmPort [www.immpo rt.org; study SDY997]). 
No significant batch effects were detected by the AMP Systems 
Biology Group. CytoF staining data has been analyzed for signifi-
cant immune cell cluster changes and to determine which markers 
provided the most useful information for single- cell phenotyping. 
In general, we observed that circulating immune cell subsets from 
patients with SLE were significantly more different from healthy 
controls than were blood immune cells from patients with RA. Sev-
eral interesting findings included a significant increase in circulating 
activated CD57+ CD8 T cells, altered ratios of Vδ1 and Vδ2 γδ 
T cell receptor, and reduced NK cell percentages in patients with 
SLE compared with controls (Lederer J: personal communication).
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The next generation phase 2 CytoF panels have removed 
uninformative antibodies and expanded marker detection on those 
immune cell subsets showing significant differences between SLE 
and RA patients and healthy controls. The phase 2 AMP panels 
will include 45 markers per panel with new advances in metal iso-
tope antibody labeling methods. In phase 2, blood immune cells 
from as many as 400 SLE and RA patients will be profiled using 
newly designed antibody panels that are T cell, B cell, innate cell, 
and neutrophil centric. We anticipate that the results from AMP 
phase 2 will identify immune cell phenotypes that could be used 
to diagnose, predict, or better understand the pathobiology of the 
SLE disease process.
Conclusion
Phase 1 lupus AMP studies have identified novel inflam-
matory cell populations and their origins, have begun to identify 
possible molecular biomarkers for disease response, and have 
suggested that it may eventually be possible to use noninva-
sive cell collections to longitudinally study the renal landscape. 
Together, the phase 1 studies set the stage for phase 2 analysis 
of renal tissue from 160 well- characterized patients with LN from 
which both renal resident cells and immune cells will be analyzed 
using 10x Genomics technology. This will allow us to correlate 
peripheral blood cell phenotype by CytoF, the renal transcriptome, 
and the urine proteome with patient histologic subclass, response 
to therapy, and outcome at 12 months. New hypotheses can 
then be examined using more focused molecular and histologic 
 analyses in new cohorts and examination of specific molecules 
and pathways in relevant mouse models.
The AMP studies have been completed within the pre-
scribed timeframe and with organized input from many inves-
tigators, including multiple clinicians who are providing a rich 
clinical data set to accompany the genomic, proteomic, and 
CytoF studies. The phase 1 studies have demonstrated good 
patient safety, and the preliminary analyses have confirmed that 
the data is of high quality. Central storage and the ability to freeze 
and batch samples has been a key component in maintaining 
quality. The application and development of new bioinformat-
ics tools such as trajectory analysis and Harmony (17) should 
enable further novel molecular insights from the larger cohort. 
As advanced technologies become available, such as histologic 
immunophenotyping with large numbers of markers, T cell and 
B cell repertoire analysis, barcoding, and epigenetic profiling, the 
AMP organizational model can be used as a template for new 
discovery cohorts.
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